ONKURE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
ONKURE THERAPEUTICS, INC. (OKUR) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of -$54.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-03-12
- ONKURE THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-12-31 was -$54.00K.
- ONKURE THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- ONKURE THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-06-30 was $0.00.
- ONKURE THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-03-31 was $0.00.
- ONKURE THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was -$54.00K.
- ONKURE THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was -$54.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$54.00K 10-K · filed 2026-03-12 | |||
| 2024-12-31 | -$54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$54.00K derived: sum of 2 quarters · filed 2025-03-10 | -$54.00K derived: sum of 3 quarters · filed 2025-03-10 | -$54.00K 10-K · filed 2025-03-10 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-03-10 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |